Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Cloud-Based system could transform diabetes care in hospitals

NCT ID NCT05307237

Disease control Sponsor: Scripps Whittier Diabetes Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a continuous glucose monitor (CGM) that sends real-time blood sugar data to a cloud-based dashboard, allowing a remote team to manage high-risk type 2 diabetes patients in the hospital. Over 500 participants were assigned to either the active CGM system or usual care with blinded monitoring. The goal was to improve time in safe blood sugar range and reduce hospital infections.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dexcom G6 Continuous Glucose Monitor (device)
What this could lead to
If successful, this could lead to better blood sugar management and fewer infections for hospitalized diabetes patients, especially those with limited access to care.
What could go wrong
This is a completed study, but results may not apply to all hospitals or patient groups. The device requires proper training and may have technical issues or skin reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

518 people

The number who actually took part.

Started

Apr 2022

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Documented previous or current Type 2 Diabetes (T2D) diagnosis as defined by either diagnosis in the chart or an HbA1c \> or = to 6.5% in the last 90 days * Either on subcutaneous (SQ) insulin orders, or greater than two serum or Point of Care (POC) glucose \> or = 200 mg/dL in most recent 24 hours of admission Exclusion Criteria: * Anticipated length of stay \< 24 hours; * Current or anticipated ICU placement; * Does not speak English or Spanish; * Known allergy to adhesives; * Current participation in any medication or device research study; * Pregnant; * Any other condition that Multiple Principal Investigator (MPI) Philis-Tsimikas or the attending physician deems contraindicated

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes

Contacts and locations

Locations

  • Scripps Mercy Hospital

    Chula Vista, California, 91910, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.